278
Volume 5, Issue 10: Special Issue
(EJAR)
ISSN: 2181-2020
MPHAPP
THE 6TH INTERNATIONAL SCIENTIFIC AND PRACTICAL
CONFERENCE “MODERN PHARMACEUTICS: ACTUAL
PROBLEMS AND PROSPECTS”
TASHKENT, OCTOBER 17, 2025
in-academy.uz
SYNTHESIS OF IMATINIB ESSINATE AND ITS INCLUSION COMPLEXES
INHIBITING CANCER CELL PROLIFERATION
Tuymu odo a R.A.
Islomo B.R.
Saido R.R.
Tashken Pha maceu ical Ins i u e, Tashken ci y, Republic o Uzbekis an
e-mail: [email p o ec ed]
h ps://doi.o g/10.5281/zenodo.17334317
Rele ance: Cance is one o he as es -g owing diseases and anks second wo ldwide a e
ca dio ascula diseases in e ms o mo ali y. The numbe o pa ien s diagnosed wi h cance is
inc easing e e y yea , and i is p edic ed ha by 2040 abou 29.4 million new cases will be egis e ed.
Such ala ming da a highligh he u gen need o disco e new an icance d ugs and de elop e ec i e
ea men me hods. O e he pas wo decades, 237 new bioac i e subs ances ha e been de eloped
and ecommended o medical use wo ldwide o cance he apy. Mo e han 70 o hem inhibi cance
cell p oli e a ion h ough y osine kinase ecep o inhibi ion. One o hese d ugs is ima inib mesyla e.
Al hough ima inib has been success ul in cance ea men , i s use has ce ain limi a ions. Mo e han
50% o pa ien s ea ed wi h ima inib de elop esis ance, leading o he apy modi ica ion in 30–40%
o cases. In addi ion, mo e han 60% o pa ien s expe ience edema as an ad e se e ec . The e o e,
he disco e y o new an icance agen s wi h highe e icacy and ewe side e ec s emains an u gen
ask.
Objec i e: To syn hesize ima inib essina e and i s inclusion complex.
Me hods: An e hanolic solu ion o ima inib was g adually mixed wi h an e hanolic solu ion o
escin unde cons an s i ing a a con olled empe a u e o 3 hou s using a magne ic s i e . The
eac ion was ca ied ou in a non-he me ic essel a 40°C, du ing which he e apo a ion o e hanol
led o a dec ease in he solu ion olume. The inc easing iscosi y o escin may also ha e con ibu ed
o he educed mo emen o he s i ba . The solu ion g adually became ligh e in colo upon isual
obse a ion. The esul ing mix u e was hen s o ed in he da k o 16 hou s, yielding a anspa en ,
ligh g een solu ion. This solu ion was il e ed using il e pape .
Fo he syn hesis o he escima in subs ance, 0.49 g o ima inib, 1.13 g o escin, and 1.14 g o
hyd oxyp opyl-β-cyclodex in we e each dissol ed sepa a ely in 20 ml o e hanol and s i ed un il
comple e dissolu ion. A e wa ds, a a cons an empe a u e o 40°C, he escin solu ion was slowly
added o he ima inib solu ion. Hyd oxyp opyl-β-cyclodex in was hen in oduced, and he mix u e
was s i ed a 300–700 pm o 4 hou s using a magne ic s i e . The esul ing solu ion was il e ed
h ough il e pape and e apo a ed.
Resul s: The syn hesis was ca ied ou i e imes, and he a e age yields we e calcula ed,
esul ing in 89.3% o ima inib essina e and 91.8% o escima in. The ob ained subs ances we e
analyzed using Scanning Elec on Mic oscopy (SEM), Powde X- ay Di ac ion (XRD), IR and UV
spec oscopy, as well as The mog a ime ic/Di e en ial The mal Analysis (TG/DTA). Compa a i e
analyses wi h he s a ing ma e ials con i med ha he syn hesized compounds ep esen indi idual
subs ances.
Conclusion: Visual obse a ions along wi h SEM, UV, IR, TG/DTA, and XRD analyses
con i med he success ul syn hesis o ima inib essina e and escima in. Fu u e in i o and in i o
s udies will help o u he elucida e he pha macological p ope ies o hese compounds.
